

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: February 2, 2010  
Electronic Signature for Colleen McKiernan, Ph.D.: /Colleen McKiernan, Ph.D./

Docket No.: 59526(47992)  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Robert Blumenthal et al.

Application No.: 10/582,411

Confirmation No.: 1153

Filed: March 12, 2007

Art Unit: 1627

For: METHODS FOR INHIBITING HIV AND  
OTHER VIRAL INFECTIONS BY  
MODULATING CERAMIDE METABOLISM

Examiner: S. Wang

### RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

In response to the restriction requirement set forth in the Office Action mailed November 4, 2009, Applicant hereby elects for continued examination, the subject matter of **Group 1**, directed to **Claims 1, 4, 6-18, 23-33** (in part), drawn to a method of inhibiting HIV infectivity or treating HIV infection comprising administering to a patient a retinoid.

An election of a specific retinoid for the purpose of examination has been further required in this case. Applicant hereby elects N-(4-hydroxyphenyl)retinamide (fenretinide) as the species for search. Applicant submits that although the use of different retinoids are inventively distinct, the search is coextensive and does not